LIVINGLIVING
its founder, Josh Juster.. Susan Morrison,
Executive VP and Chief Administrative
Officer for Tandem, commented, "As we
were considering this, what stood out to
us was the Sugarmate application and
the response from people with diabetes
on how much they liked the app. As we
look at our future digital health offerings,
we're looking to build out an ecosystem
of diabetes products and services that
help support that overall mission. The
Sugarmate app has proven to be popular
with people who use insulin pumps
as well as people who use multiple
daily injections. It really helps visualize
diabetes therapy data in innovative ways.
It allows users to log health and nutrition
information and it can provide notifications
and alerts to the users as well as their
families. It very much helps support
people's diabetes management."
The company said Sugarmate will not
replace the upcoming t:connect mobile
app.
www.mddionline.com
Diabetes ecosystem
Biocorp has signed an agreement for
Roche Diabetes Care France to distribute
its Mallya technology to pharmacies in
France. Mallya is a two-year reusable
injector pen sensor compatible with most
disposable and reusable insulin injection
pens. It automatically collects the insulin
dose delivered with near 100% accuracy.
In the future, Mallya will also be part of the
RocheDiabetes ecosystem, consisting of
connected blood glucose meters (AccuChek Mobile, Accu-Chek Guide) and
digital solutions for better patient care.
Hypo help
As reported by Business Wire, Xeris
Pharmaceuticals has announced that
the Gvoke HypoPen now available in
the US, the first autoinjector for severe
hypoglycemia. The company is leveraging
its novel formulation technology platforms
to develop and commercialize readyto-use injectable and infusible drug
formulations. The Gvoke HypoPen is the
first ready-to-use glucagon in a premixed
autoinjector, with no visible needle. Bruce
Bode, MD, Atlanta Diabetes Associates
explains, "Gvoke HypoPen allows the
diabetes community to change how
we approach treating severe low blood
sugar events. Anyone can use
Gvoke HypoPen in two simple
steps. That opens the door for
some patients to even give it to
themselves, in certain situations.
My hope is that what was once
considered a crisis moment,
can now become a manageable
situation with Gvoke HypoPen."
INTEGRATION SENSATIONS
Above: Roche Diabetes Care
France's new agreement
with Biocorp for its Mallya
inulin pen. Below, the Gvoka
HypoPen.